Have a feature idea you'd love to see implemented?
Let us know!
KYTX Kyverna Therapeutics Inc.
Price (delayed)
$3.99
Market cap
$172.25M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$29.45
Enterprise value
$76.16M
We are a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our goal is to bring disease-modifying therapeutic benefits to patients suffering from
Highlights
Kyverna Therapeutics's EPS has soared by 59% YoY and by 43% from the previous quarter
Kyverna Therapeutics's debt has decreased by 9% QoQ and by 5% YoY
Kyverna Therapeutics's quick ratio has soared by 126% YoY but it has decreased by 30% from the previous quarter
The net income has dropped by 130% year-on-year and by 21% since the previous quarter
KYTX's gross profit has dropped by 100% year-on-year
Key stats
What are the main financial stats of KYTX
Market
Valuations
Earnings
Shares outstanding
43.17M
Market cap
$172.25M
Enterprise value
$76.16M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.57
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$110.49M
EBITDA
-$106.15M
Free cash flow
-$97.76M
Per share
Balance sheet
Liquidity
EPS
-$29.45
Free cash flow per share
-$2.27
Book value per share
$7.02
Revenue per share
$0
TBVPS
$7.86
Total assets
$339.2M
Total liabilities
$36.49M
Debt
$9.14M
Equity
$302.71M
Working capital
$294.39M
Debt to equity
0.03
Current ratio
10.5
Quick ratio
10.4
Net debt/EBITDA
0.91
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-37.9%
Return on equity
-51.1%
Return on invested capital
-72.1%
Return on capital employed
-35.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KYTX stock price
How has the Kyverna Therapeutics stock price performed over time
Intraday
-3.16%
1 week
-16.88%
1 month
-23.27%
1 year
N/A
YTD
N/A
QTD
-18.4%
Financial performance
How have Kyverna Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$122.94M
Net income
-$110.66M
Gross margin
N/A
Net margin
N/A
KYTX's operating income has shrunk by 147% YoY and by 22% QoQ
The net income has dropped by 130% year-on-year and by 21% since the previous quarter
KYTX's gross profit has dropped by 100% year-on-year
The revenue has plunged by 100% YoY
Growth
What is Kyverna Therapeutics's growth rate over time
Valuation
What is Kyverna Therapeutics stock price valuation
P/E
N/A
P/B
0.57
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Kyverna Therapeutics's EPS has soared by 59% YoY and by 43% from the previous quarter
KYTX's equity is down by 9% since the previous quarter
The revenue has plunged by 100% YoY
Efficiency
How efficient is Kyverna Therapeutics business performance
The company's return on equity rose by 37% QoQ
The company's return on assets rose by 27% YoY and by 4.8% QoQ
KYTX's ROIC is up by 9% QoQ and by 7% YoY
Dividends
What is KYTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KYTX.
Financial health
How did Kyverna Therapeutics financials performed over time
Kyverna Therapeutics's quick ratio has soared by 126% YoY but it has decreased by 30% from the previous quarter
The current ratio has soared by 123% YoY but it has contracted by 29% from the previous quarter
Kyverna Therapeutics's debt is 97% lower than its equity
KYTX's debt to equity has soared by 133% YoY
Kyverna Therapeutics's debt has decreased by 9% QoQ and by 5% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.